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Background: Accumulating evidence supports an effect of aspirin in reducing overall cancer incidence and mortality in
the general population. We reviewed current data and assessed the beneﬁts and harms of prophylactic use of aspirin in
the general population.
Methods: The effect of aspirin for site-speciﬁc cancer incidence and mortality, cardiovascular events was collated from
the most recent systematic reviews. Studies identiﬁed through systematic Medline search provided data regarding
harmful effects of aspirin and baseline rates of harms like gastrointestinal bleeding and peptic ulcer.
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Results: The effects of aspirin on cancer are not apparent until at least 3 years after the start of use, and some beneﬁts
are sustained for several years after cessation in long-term users. No differences between low and standard doses of
aspirin are observed, but there were no direct comparisons. Higher doses do not appear to confer additional beneﬁt but
increase toxicities. Excess bleeding is the most important harm associated with aspirin use, and its risk and fatality rate
increases with age. For average-risk individuals aged 50–65 years taking aspirin for 10 years, there would be a relative
reduction of between 7% (women) and 9% (men) in the number of cancer, myocardial infarction or stroke events over a
15-year period and an overall 4% relative reduction in all deaths over a 20-year period.
Conclusions: Prophylactic aspirin use for a minimum of 5 years at doses between 75 and 325 mg/day appears to have
favourable beneﬁt–harm proﬁle; longer use is likely to have greater beneﬁts. Further research is needed to determine the
optimum dose and duration of use, to identify individuals at increased risk of bleeding, and to test effectiveness of
Helicobacter pylori screening–eradication before starting aspirin prophylaxis.
Key words: aspirin, prevention, beneﬁt-harm, cancer, cardiovascular disease, gastrointestinal bleeding
introduction
Aspirin reduces the incidence of cardiovascular events by 12%,
both in the general population and in high-risk groups [1].
However, with increasing awareness of risk factors and the wide
range of effective agents available for high-risk individuals, use
of aspirin in the general population does not have a major
impact on cardiovascular mortality. An increasing body of evi-
dence supports the role of aspirin for cancer prevention [2–7].
Aspirin use is associated with an age-dependent increased risk
of bleeding [8], especially gastrointestinal (GI) bleeding, and
peptic ulcer; and beneﬁts need to be balanced against harms.
The US Preventive Services Task Force (USPSTF) have reported
on beneﬁts and harms of aspirin use for prevention of speciﬁc
diseases like colorectal cancer (CRC) [9] and cardiovascular
disease (CVD) [10]. However, they have not investigated overall
beneﬁts and harms based on all major diseases. A recent eco-
nomic model incorporating aspirin’s effect on cancer has sug-
gested that prophylactic aspirin use can be cost-effective [11].
Previously, we reviewed the role of aspirin for cancer preven-
tion [12]. Although there was strong evidence for protection
against colorectal and other cancers [13], we concluded that it
was premature to recommend routine use in the general popula-
tion and recommended further long-term follow-up of existing
aspirin trials. Since our publication, several such extended
follow-up results have become available from initiatives under-
way at the time. As a result, an augmented group reconvened on
6 May 2011 to review current data and assess the beneﬁts and
harms of prophylactic use of aspirin in the general population.
A substantial amount of the new data we considered and used
for the beneﬁt-harm analyses were unpublished at that time
[3, 5–7, 14], and the group concluded that it should be publicly
available before we report our review. Most of these data are
now published. Here, we summarise current evidence regarding
the effect of aspirin on cancer and estimate overall beneﬁts and
harms of prophylactic aspirin use.
methods
materials: evidence and data collation
The evidence for the effect of aspirin for incidence and death by
cancer site was collated from the most recent systematic reviews
[2–7] and some individual studies reporting on speciﬁc sites or
long-term aspirin use [15–18]. Systematic reviews were under-
taken by the members of the group and these data, although
only published subsequently, were available for discussion at the
evidence review meeting (Table 1). Cancer incidence and mor-
tality rates in the UK for year 2008 [19] were used for baseline
rates.
The evidence for the effect of aspirin on cardiovascular events
was based on the Antithrombotic Trialists’ (ATT) Collaboration
meta-analysis [1]. Baseline CVD incidence and mortality rates
are based on a downward adjustment of the rates observed in
the UK in 1998 [20], to reﬂect a 25% reduction in incidence [21]
and a 30% reduction in mortality as seen in the USA [22] (UK
shows similar trends) between 1998 and 2008 to project the
rates forward.
A detailed analysis of the harmful effects of aspirin has been
reported elsewhere [23] and is summarised brieﬂy in the supple-
mentary Material, available at Annals of Oncology online.
statistical analysis: beneﬁt–harm analysis
We considered the overall beneﬁts and harms for taking aspirin
for 10 years starting from age 50, 55, 60 and 65 years separately
for men and women. We assumed: (i) that the cardiovascular
beneﬁt and adverse-effects (Table 2) only occur during active
treatment, i.e. 10 years; (ii) the protection against cancer begins
3 years after initiating aspirin [3] and continues for an addition-
al 5 years after stopping aspirin [24]; (iii) the protection against
cancer mortality begins 5 years after the commencement of
aspirin use [2] and lasts for an additional 10 years after treat-
ment cessation and (iv) the protective effects are seen only in
colorectal, oesophageal, gastric, breast, prostate and lung
cancers (Table 3) [or only colorectal, oesophageal and gastric
cancers for sensitivity analyses]. Details of derivation of effect
sizes (Table 3) used for beneﬁt–harm analyses are given in the
supplementary Material, available at Annals of Oncology online.
The inter-current mortality (England and Wales, 2008)
adjusted rates were used to compute the probabilities for differ-
ent events by computing 1− exp(−inter-current mortality
adjusted cumulative hazard) for incidence (not mortality) calcu-
lations. The calculations for the incidence of major events
(cancer, myocardial infarction, stroke, major bleeding) excluded
uncomplicated peptic ulcers or other more minor bleeding
events since they are not comparable in severity.
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ﬁndings
summary of evidence for a reduction in cancer
incidence and mortality
The main results are summarised in Table 1.
colorectal cancer. There is now overwhelming evidence for a
reduction in CRC incidence and mortality from regular aspirin
use. A 20-year follow-up of two high-dose aspirin trials showed
an overall 37% reduction in CRC incidence in participants who
had scheduled treatment of 5 years or more, but the effect was
seen only 10 years after randomisation [13]. Subsequent long-
term follow-up of three trials of low-dose aspirin (75–300 mg/
day) use found a smaller (25%) but signiﬁcant reduction in CRC
incidence [4]. The effects were not apparent immediately and
showed larger beneﬁt with increasing duration of aspirin use.
Two trials of alternate day use, the Women’s Health Study
(WHS) [17] and the Physicians’ Health Study (PHS) [28], have
not shown any reduction within 10 years of follow-up; although
a 43% reduction after 10 years has been observed in the WHS
[14]. Evidence for mortality reduction is based on a greater
number of studies [2] and the effect size appears to be larger
than for incidence—a 40% overall reduction or 52% reduction
with at least 5 years of scheduled treatment [2, 4]. Rothwell et al.
[5] suggest that the greater effect on mortality is due to a
reduction in metastatic spread, possibly through a platelet-
mediated mechanism with beneﬁts both before and after the
diagnosis of cancer [29, 30].
The effects from observational studies are based on a much
larger number of cases and are largely consistent with those
from RCTs (Table 1)—a 27% overall reduction in CRC inci-
dence (38% in case–control studies, 19% in cohort studies) [6, 7].
Although not clearly observed for other cancers, observational
studies show larger reductions for standard or high-dose aspirin
compared with low-dose aspirin for CRC [7].
Aspirin shows similar effects in individuals at high-risk of CRC
[31]. Colorectal Adenoma/Carcinoma Prevention Programme 2
(CAPP2), a randomised trial of 600 mg aspirin daily in carriers of
Lynch syndrome, showed a 63% reduction (P = 0.008) in inci-
dence among those completing 2 years of treatment, although
results with shorter follow-up [32] or for ﬁrst events in all en-
rolled patients were not signiﬁcant [31].
oesophageal cancer. Although data are less extensive, consistent
reductions in mortality have also been seen for oesophageal
cancer, with a 58% reduction after 5 years of follow-up in
randomised trials, and a 44% reduction in cohort studies [25, 26].
A 43% reduction in incidence of oesophageal cancer was seen
in case–control studies, whereas cohort studies reported a 27%
reduction. Although the meta-analyses of RCTs have suggested
the effect of aspirin is primarily on adenocarcinomas (all sites),
the observational studies [7] have found similar reductions in
squamous cell (39%) and adenocarcinomas (36%) including
gastric cardia.
other gastrointestinal cancers. Stomach cancer also emerges as
a site for which aspirin may provide substantial protection,
although the extent of the effect appears to be smaller, and the
data are less extensive and more variable. In the RCTs, an
overall 31% reduction in deaths was reported (P = 0.11), based
mostly on a 58% reduction (P = 0.007) after 10 years of use [2].
A 41% reduction in mortality was also observed in two cohort
studies [25, 26]. Case–control studies found a 39% reduction in
gastric cancer incidence while cohort studies reported a 25%
reduction. Pancreatic cancer appears to be little affected with a
non-signiﬁcant 4% reduction in incidence and 3% reduction in
mortality [25, 27] in cohort studies and a non-signiﬁcant 19%
reduction in mortality in the RCTs. Case–control studies
showed a non-signiﬁcant 7% reduction in incidence.
other sites. At most small effects are seen at other cancer sites.
Case–control studies indicate an 18% reduction in breast cancer
incidence, and an 8% reduction was seen in cohort studies. A
similar but non-signiﬁcant reduction in mortality [16, 25, 26]
was seen; 5% in case–control studies and 14% in cohort studies.
However, no effect on incidence was seen in the WHS [17]. A
non-signiﬁcant increase in breast cancer mortality was seen in
the overview of RCTs [6], although this may be unreliable in
view of the small number of events.
Some effect has also been seen for prostate cancer with a non-
signiﬁcant 19% reduction in mortality in the RCTs, and a non-
signiﬁcant 16% reduction in lethal prostate cancers (metastatic
or fatal) in the Health Professionals Follow-up study (HPFS)
[18]. A signiﬁcant 9% reduction in incidence in cohort studies
has been observed. Case–control studies show a signiﬁcant 13%
reduction when analyses are restricted to aggressive (high-grade)
tumours, with a non-signiﬁcant 14% reduction overall [7].
More variable but generally favourable evidence was seen for
lung cancer, with a 29% reduction in mortality in the RCTs,
which became apparent only after 5 years of follow-up, and a
non-signiﬁcant 12% reduction in mortality in one case–control
study [16] and a 19% reduction in one cohort study [25]. The
effect on incidence in observational studies was conﬁned to
case–control studies (19% reduction) with no effect seen in
cohort studies.
Although a large reduction in endometrial cancer was seen in
one study of patients with mismatch repair defects [31], its rele-
vance to the general population is unknown and a signiﬁcant
preventive effect of aspirin has not been seen for any other
cancer site, either for incidence or mortality.
dose and duration. There is consistent evidence that long-term
use of aspirin is necessary to achieve a cancer prevention
beneﬁt. This is most clearly seen in the RCTs where no beneﬁt
was seen in years 0–3, but incidence was reduced after 3 years of
treatment [3], and mortality was reduced only after 5 years [2, 3],
but continued for as long as follow-up was available. This is
supported by observational studies, especially for CRC where the
reduced incidence is much clearer in long-term users [6, 7, 24].
Reduced incidence and mortality have been seen for all daily
doses above 75 mg, and there is no clear indication of a greater
reduction with increasing dose [4] in average-risk individuals.
Some observational studies have suggested that doses <300 mg/
day are not effective [24, 33] and an RCT [31] in high-risk
individuals has shown efﬁcacy at 600 mg daily dose. However,
Baron et al. [34] observed greater reductions in all or advanced
colorectal adenomas with an 81 mg daily aspirin compared with
a 325 mg daily dose. In a meta-analysis of colorectal adenoma
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Table 1. Relative risks of aspirin use on the incidence and mortality of major cancers from recent overviews and major studies
Cancer incidence Cancer mortality
No. of studies and source No. of cases Relative risk (95% CI) No. of studies and source No. of cases Relative risk (95% CI)
Colorectal cancer
Case–control 15a 21 414 0.63 (0.56–0.70) 1b 433 0.72 (0.56–0.92)
22c 17 231 0.61 (0.55–0.67)
Cohort 15a 16 105 0.82 (0.75–0.89) 2d 1124 0.68 (0.56–0.83)
8c 2955 0.78 (0.71–0.84) 1*e 149 0.64 (0.42–0.98)
RCT 3f 196 0.75 (0.56–0.97) 3f 130 0.61 (0.43–0.87)
3*f 135 0.62 (0.43–0.94) 3*f 91 0.48 (0.30–0.77)
Oesophageal cancer
Case–control 7a 1075 0.54 (0.44–0.67) – – –
9c 2307 0.58 (0.44–0.76)
Cohort 4a 1118 0.73 (0.51–1.07) 2d 194 0.56 (0.35–0.91)
1c 102 0.78 (0.42–1.44) 1*e 45 0.61 (0.30–1.23)
RCT – – – 3g 62 0.42 (0.25–0.71)
Stomach cancer
Case–control 7a 2411 0.60 (0.44–0.82) – – –
8c 3000 0.61 (0.40–0.93)
Cohort 6a 2108 0.77 (0.58–1.04) 2d 314 0.59 (0.40–0.86)
1c 184 0.49 (0.22–1.12) 1*e 39 0.36 (0.15–0.88)
RCT – – – 3g 71 0.69 (0.43–1.10)
Pancreatic cancer
Case–control 3a 1406 0.82 (0.68–1.00) – – –
5c 1619 1.02 (0.83–1.26)
Cohort 7a 6471 0.95 (0.85–1.05) 2h 4655 0.97 (0.86–1.09)
3c 2415 1.00 (0.79–1.27) 1*e 186 1.03 (0.73–1.46)
RCT – – – 3g 77 0.81 (0.51–1.26)
Lung cancer
Case–control 5a 4863 0.73 (0.55–0.98) 1b 979 0.88 (0.73–1.05)
12c 11 683 0.84 (0.66–1.08)
Cohort 15a 11 356 0.98 (0.92–1.05) 2i 410j 0.97 (0.83–1.14)
5c 1856 1.07 (0.96–1.19) 1*e 462 1.04 (0.84–1.29)
RCT – – – 3g 326 0.71 (0.58–0.89)
Prostate cancer
Case–control 9a 5795 0.87 (0.74–1.02) – – –
8c 7857 0.86 (0.69–1.08)
Cohort 15a 31 657 0.91 (0.85–0.97) 1k 580m 0.84 (0.69–1.02)
5c 3865 0.93 (0.86–1.01) 1*e 43 0.57 (0.28–1.15)
RCT – – – 3g 210 0.81 (0.61–1.06)
Breast cancer
Case–control 10a 25 835 0.83 (0.76–0.91) 1b 864 0.95 (0.80–1.13)
12c 22 046 0.81 (0.72–0.93)
Cohort 22a 27 091 0.93 (0.87–1.00) 2d 131j 0.86 (0.65–1.15)
9c 7713 0.88 (0.82–0.93) 1*e 32 0.28 (0.06–1.20)
RCT 1n 1230 0.98 (0.87–1.09) –c 23 1.17 (0.50–2.71)
Several studies appear in more than one overview.
A number of cases are the number of events, either cancer diagnoses or cancer deaths.
*Relative risks for >5 years daily use are also given where available.
aFrom Bosetti et al. [7].
bFrom Chan et al. [16] (Women only Nested Case–control study, current users versus never users).
cFrom Algra et al. [6] (based on maximum aspirin use data).
dPooled risk ratios from Ratnasinghe et al. [25] and Thun et al. [26].
eFrom Jacobs et al. [15].
fFrom Rothwell et al. [4].
gFrom Rothwell et al. [2].
hPooled risk ratios from Ratnasinghe et al. [25] and Jacobs et al. [27].
iPooled risk ratios from Ratnasinghe et al. [25] and Thun et al. [26]; Thun et al. [26] reported all respiratory cancer deaths as one group, which
have been approximated as lung cancer deaths.
jNumber of deaths (lung cancer or breast cancer) not reported in Cancer Prevention Study II, Thun et al. [26].
kFrom Dhillon et al. [18].
mNumber of lethal prostate cancers, i.e. any metastatic prostate cancer or prostate cancer death.
nFromWomen’s Health Study, Cook et al. [17].
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prevention trials, similar reductions were observed with low-
(81 or 160 mg daily) versus standard-dose (300 or 325 mg daily)
aspirin, but reductions in advanced adenomas were greater with
the higher dose [35]. Of the alternate daily dosing trials WHS
[17] and PHS [28, 36]; PHS [28, 36] has not shown clear
beneﬁts, whereas WHS has shown a delayed post-treatment
beneﬁt in CRC incidence [14].
age and sex. In an overview of six RCTs of daily low-dose
aspirin involving over 35 000 individuals and 1632 incident
cancers, no difference has been seen between men and women,
or between those aged <60 years of age at randomisation versus
older ages [3]. These results appear robust, as ∼40% of these
cancers occurred in women and 30% in individuals younger
than 60 years of age at randomisation [3]. Observational studies
generally support this ﬁnding, but data are less complete. A
possible exception to these ﬁndings is the smaller and late effect
seen in the WHS, which investigated 100 mg aspirin on
alternate days in women only [17].
cardiovascular disease
When used in primary prevention settings, aspirin has been shown
to reduce serious vascular events among individuals at average/
low risk [1] by 12% (0.51% versus 0.57%/year, P = 0.0001). This
was primarily due to a 21% reduction in non-fatal myocardial
infarction (MI), with little overall effect on strokes. Overall
effects on serious vascular events were similar in men and
Table 3: Risk ratios for incidence and mortality of different events due to aspirin use; used in benefit-harm calculations.
Event Incidence Mortality
Best estimate Conservative Best estimate Conservative
Colorectal cancer 0.65 0.70 0.60 0.65
Oesophageal cancer 0.70 0.75 0.50 0.55
Gastric cancer 0.70 0.75 0.65 0.70
Lung cancer 0.95 1.00 0.85 0.90
Prostate cancer 0.90 0.95 0.85 0.90
Breast cancer 0.90 0.95 0.95 1.00
Myocardial infarction 0.82 0.82 0.95 0.95
Stroke 0.95 0.95 1.21 1.21
Major extracranial bleeding 1.54 1.70 - -
GI bleeding - - 1.60 1.70
Peptic Ulcer - - 1.60 1.70
A qualitative estimation of site-specific relative risks for various cancers is done based on data in Table 1 as described in the supplementary material,
available at Annals of Oncology online, the relative risks for cardiovascular events are based on the ATT Collaboration meta-analysis [1] and those for
adverse gastrointestinal events are estimated as described elsewhere [23].
Table 2: Age and Sex specific baseline major extracranial bleeding [1], any GI Bleeding [51, 52], peptic ulcer [51] and any GI complication (GI bleed
or peptic ulcer) event rates estimated in the UK general population (per 1000 person years) not using NSAID.
Age-group (y) Major extracranial
Bleeding
Any GI
bleeding
Uncomplicated Peptic
ulcer
Any GI
complication
Men Women Men Women Men Women Men Women
50–54 0.44 0.22 1.31 0.76 0.60 0.52 1.91 1.28
55–59 0.78 0.39 1.04 0.86 0.77 0.64 1.81 1.50
60–64 1.12 0.56 2.41 1.28 0.95 0.78 3.36 2.06
65–69 1.46 0.74 3.19 2.27 1.17 0.95 4.36 3.22
70–74 1.81 0.92 4.38 2.66 1.27 1.04 5.65 3.70
75–79 2.27 1.21 7.00 4.46 1.30 1.09 8.30 5.55
80–84 2.95 1.75 8.21 6.41 1.30 1.09 9.51 7.50
GI Bleeding and peptic ulcer rates are adjusted for baseline NSAID use (18-25%) in the population. Details of estimation of these rates are reported
elsewhere [23].
Uncomplicated peptic ulcers refer to ulcers that are neither bleeding nor perforated.
Any GI bleeding comprises of both upper and lower GI bleeding, including bleeding from peptic ulcer. Any GI complication comprises of any GI
bleeding and uncomplicated peptic ulcers.
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women, although the effect of aspirin on coronary heart disease
was larger in men and the effect on stroke was larger in women.
Despite the effect on incidence, no reduction has been seen in
cardiovascular mortality in the primary prevention trials [rela-
tive risk (RR) = 0.97, 95% conﬁdence interval (CI) = 0.87–1.09
ATT Collaboration [1]; odds ratio (OR) = 0.99, 95% CI = 0.87–
1.12, Rothwell et al. [3]], although some reduction has been seen
in the high-risk individuals in the secondary prevention trials
(RR = 0.91, 95% CI 0.82–1.00, P = 0.06) [1].
bleeding and other side-effects
Without a doubt increased bleeding is the most important
side-effect of aspirin. The side-effects are discussed brieﬂy in the
supplementary Material, available at Annals of Oncology online
and more fully elsewhere [23] (Table 2). Haemorrhagic stroke,
although rare, is the most serious and potentially fatal side-
effect. Estimates suggest a relative increase of 32%–36% in
haemorrhagic strokes in aspirin users from a baseline rate of
0.03% per year [1]. Much commoner are the extracranial (pre-
dominantly gastrointestinal) bleeds, where the risk for major
events is increased by about 30%–70% from an overall baseline
risk of 0.7 per 1000 per year with low or standard-dose aspirin
treatment [23]. Overall, the rates of gastrointestinal complica-
tions increase steeply beyond age 70 years and fatality rates show a
similar trend, but the rates and fatality ratios are low below 70
years of age [23].
overall beneﬁts and harms of aspirin prophylaxis
in the general population
Using our ‘best estimates’ for individuals taking aspirin for 10
years, there would be a ‘relative’ reduction of ∼9% in the number
of men and 7% in the number of women with a cancer, myocar-
dial infarction or stroke event over a 15-year period (Table 4).
‘Absolute’ reductions are age and sex dependent. There would be
between 0.95% (women starting at age 50 years) and 3.84%
(men starting at age 65 years) fewer individuals with cancer,
myocardial infarction or stroke (Table 4). Reductions in cancer
incidence would account for 61%–80% of the overall beneﬁt, and
reductions in CRC alone would account for 30%–36% of it. Our
conservative estimate gives absolute reductions ranging from
0.68% to 3.09% (Table 4). Depending on age and sex, major
bleeding events would increase (absolute) by between 0.16%
(0.21%) and 0.81% (1.05%) over their baseline rates of 0.57% to
2.37% over a 15-year period (conservative estimates in paren-
theses). Thus, the net relative beneﬁt on these serious events is
about 6% (4% conservative) in both men and women, but abso-
lute beneﬁts are greater in men and at older ages, due to higher
baseline event rates and range from 0.79% (0.47%) to 3.03%
(2.03%). The number needed to treat (NNT) for 10 years ranges
from 33 to 127 to prevent one major event.
The magnitude of the relative reduction in cancer deaths is
somewhat larger than that for incidence (13% in men and 9% in
women) leading to a 4% (3% conservative estimate) relative re-
duction in all deaths, since there is no net reduction in cardio-
vascular or other deaths (Table 5). The net absolute beneﬁts are
slightly smaller than for incidence due to lower baseline rates.
There would be between 0.47% (0.31%) (women starting at age
50 years) and 2.18% (1.64%) (men starting at age 65 years)
fewer deaths (net beneﬁt) over a 20-year period, with NNTs to
save one life ranging from 46 to 213 (conservative estimates in
parentheses). This is almost entirely (89%–96%) due to a reduc-
tion in deaths from cancer. The beneﬁts of aspirin are at least
equivalent in magnitude to those from statins [37], and as they
mostly relate to cancer, are complimentary to statins. Although
the relative beneﬁt is similar, the absolute magnitude of beneﬁt
is smaller for women than for men as they have a lower baseline
death rate from these major diseases (Figure 1). The net absolute
beneﬁt is 2% or more (incidence or deaths) in men starting
aspirin at age 60 years or above. Calculations for 5 years of
aspirin use show similar trends (supplementary Tables W1 and
W2, available at Annals of Oncology online), but net beneﬁts are
∼50% of those for 10 years of use for major event incidence and
60% for deaths.
discussion
When based solely on the primary prevention of CVD, the value
of aspirin prophylaxis in the general population is uncertain,
because even though a reduction in vascular events is achieved, it
is accompanied by an increase in major bleeding and there is no
signiﬁcant reduction in vascular deaths [1]. Thus, analyses based
only on effects on CVD beneﬁts have suggested that aspirin is
cost-effective only in individuals at high risk of CVD [38–40].
However, recent evidence suggests that aspirin’s effect on overall
mortality is mainly through a reduction in cancer deaths [2, 3,
41]. Other studies of incidence have also supported a role for
aspirin in cancer prevention [3, 4, 6, 7, 14]. A simple economic
model assuming a 22% reduction in all cancer mortality has sug-
gested that aspirin could be cost-effective even in individuals
without CVD risk factors, [11]. However, this model has used a
very optimistic estimate for aspirin’s impact on cancer mortality,
and does not consider the impact of age and sex on beneﬁts and
harms. It also does not address the most appropriate duration of
use and is likely to be simplistic and overly optimistic. Here, we
have synthesised all available evidence of aspirin’s effects on indi-
vidual cancers, CVD and its harms. We modelled these effects
using population data from the UK for both sexes across different
age groups to analyse beneﬁts and harms of prophylactic aspirin
use in the average-risk general population in the developed world.
Although cancer incidence and/or mortality vary to some degree
across the developed world, with small overall adjustments for
this, our results are likely to be generalisable to other countries in
Western Europe and North America.
uncertainties in beneﬁts
Three members of the group (EJJ, NRC and JAJ) felt that the
evidence is still too limited to include reductions in breast, pros-
tate and lung cancer in analyses of the beneﬁts and harms of
aspirin use, and favoured a more conservative analysis that
included reductions in only colorectal, oesophageal and stomach
cancer. However, the balance of beneﬁts and harms in such ana-
lysis (supplementary Online Tables W3 and W4, available at
Annals of Oncology online) still appears favourable, although
fewer individuals would beneﬁt (and the same number would be
harmed). Analyses with cancer beneﬁt restricted to CRC alone
also show net beneﬁt across all age groups and in both sexes (data
not shown), although we claim that these are excessively
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conservative. Furthermore, uncertainties also exist due to the
impact CRC screening may have on CRC prevention by aspirin.
Complexities in the use of CRC screening methods, their variable
uptake and interplay of aspirin use with sensitivity of screening
methods make it almost impossible to predict the magnitude of
impact of CRC screening on aspirin beneﬁt in future.
Uncomplicated peptic ulcers or other minor bleeding events have
been excluded in these calculations since they are not comparable
in severity. However, these have effects on morbidity, quality of
life and the associated medical expense should also be considered.
It should also be recognised that our best estimates may be
conservative, as bigger effects have been seen in several studies,
and the overview of trials with long-term follow-up found a
20% relative mortality reduction in all cancers [2]. In addition,
the results from RCTs are based on randomised allocation to
aspirin and the effects of actual usage could be larger due to
cross-over and non-compliance. Recent results using updated
aspirin usage [15] from the CPS-II Nutrition Cohort subset
show a 16% reduction in cancer mortality in both sexes com-
bined. This is comparable with our main estimates.
These beneﬁt–harm calculations are based on data from the
developed world. Further research is needed to determine the
beneﬁts and harms in the developing world, where cancer inci-
dence is lower and Helicobacter pylori prevalence is higher.
minimising harm
Although often not as serious as MI, stroke or cancer for the age
groups considered here, major bleeding is the most important
serious side-effect of aspirin. Efforts to identify high-risk indivi-
duals and either reduce their risk or not offer them prophylactic
aspirin would greatly improve the beneﬁt–harm ratio. Clear
contraindications are those with peptic ulcer, recent bleeding
episodes or bleeding tendencies. Other risk factors for bleeding
in aspirin or non-steroidal anti-inﬂammatory drug (NSAID)
users are: increasing age, male sex, diabetes, hypertension, being
overweight or obese, smoking, alcohol consumption and H.
pylori infection [1, 42]. Age is a key factor in weighing beneﬁts
and harms, with a roughly doubling of risk with each advancing
decade of age. If aspirin has a long-term post-treatment carry-
over beneﬁt after more than 5 years of use, restricting prophylac-
tic use to age <70 years in average-risk individuals may be
prudent at this stage. However, since the cancer risk also
increases steeply with age, use at older ages may be beneﬁcial if
the carry-over beneﬁt of aspirin is limited. The increased risk of
bleeding in men is not a useful factor in restricting use, because
men also have greater beneﬁts. Increased bleeding risk in
smokers is a more serious issue, but clearly smoking cessation is
a more important preventive action where possible. The risk of
Table 4. Benefits and harms of 10 years of aspirin use on the incidence of major events by age and sex
Age at starting 50 years 55 years 60 years 65 years
Incidence Baseline Reduction Baseline Reduction Baseline Reduction Baseline Reduction
Cancer
Men 9.70 0.92 (0.65) 15.20 1.52 (1.07) 20.75 2.09 (1.45) 25.39 2.51 (1.75)
Women 10.41 0.76 (0.48) 13.19 1.03 (0.67) 15.78 1.26 (0.85) 18.08 1.48 (1.03)
MI
Men 5.13 0.52 6.75 0.68 8.72 0.89 10.92 1.15
Women 1.62 0.15 2.59 0.23 4.22 0.37 6.69 0.61
Stroke
Men 2.14 0.06 3.16 0.08 4.66 0.12 6.66 0.18
Women 1.71 0.05 2.54 0.07 3.84 0.10 5.75 0.15
Total
Men 16.97 1.50 (1.22) 25.11 2.29 (1.83) 34.13 3.10 (2.47) 42.97 3.84 (3.09)
Women 13.74 0.95 (0.68) 18.32 1.32 (0.97) 23.83 1.73 (1.32) 30.53 2.24 (1.79)
Adverse events Baseline Excess Baseline Excess Baseline Excess Baseline Excess
Major extracranial bleeding
Men 1.12 0.32 (0.42) 1.58 0.49 (0.64) 2.00 0.66 (0.85) 2.37 0.81 (1.05)
Women 0.57 0.16 (0.21) 0.81 0.25 (0.32) 1.05 0.34 (0.44) 1.30 0.43 (0.55)
Net benefit Baseline Reduction Baseline Reduction Baseline Reduction Baseline Reduction
Men 18.09 1.18 (0.81) 26.70 1.80 (1.19) 36.13 2.44 (1.62) 45.34 3.03 (2.03)
Women 14.31 0.79 (0.47) 19.13 1.07 (0.65) 24.88 1.39 (0.88) 31.83 1.82 (1.24)
Baseline probabilities of an event and aspirin-related reductions (per 100 individuals in 15 years) using best (and conservative) estimates for
prophylactic use of aspirin for 10 years on the incidence of major events namely cancer, myocardial infarction, stroke and major bleeding according to
sex and age at starting use. All estimates are adjusted for inter-current mortality.
Effects on cardiovascular and bleeding events are assumed to occur only during active treatment (10 years) and those for cancer do not start until after
3 years of use but persist for an additional 5 years after treatment completion. Baseline rates are for the entire 15-year period. Figures in parentheses are
conservative estimates.
The figures in bold represent overall benefits, overall harms and net balance of benefit and harm.
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gastrointestinal bleeding increases with increasing alcohol con-
sumption [42], and aspirin increases this risk at all levels of con-
sumption. Caution is necessary for prophylactic use in those
with high alcohol consumption.
In NSAID users, H. pylori infection is associated with a 2-
to 3.5-fold higher risk of uncomplicated peptic ulcer, and with
a 2- to 2.5-fold higher risk of gastrointestinal bleeding [23, 43,
44]. We estimate it to account for about 25%–30% of peptic
ulcers [23] and upper gastrointestinal ulcer bleeding events in
NSAID users. There is limited evidence [45, 46] on an H.
pylori screen-and-treat strategy before starting aspirin. Studies
investigating the cost-effectiveness of H. pylori screening to
prevent gastric cancer [47, 48] support it in general but a trial
will provide better quality evidence. HEAT trial in aspirin
users (ClinicalTrials.gov Identiﬁer: NCT01506986) is sched-
uled to start soon. Concomitant use of proton pump inhibitors
(PPIs) reduced adverse GI events by 66% (OR 0.34; 95% CI
0.21–0.57) in a meta-analysis of 35 trials [49]. The role of
routine prolonged use of PPIs in the general population is less
clear. The ongoing AspECT trial [50] is addressing the question
as to whether co-administration of PPIs with aspirin will be
effective in reducing peptic ulcer disease and gastrointestinal
bleeding, but in a population that will mostly not be infected with
H. pylori.
research priorities
Several uncertainties exist in our estimates which would beneﬁt
from more data. Key among these is the extent of a carry-over
effect after stopping aspirin. This is an important issue in deter-
mining the most appropriate duration of use, which could be
longer than the 10 years used in our base case scenario. In rando-
mised trials, the effects on cancer mortality persisted for several
years after the end of the 5- to 9-year intervention period [2].
However, the extent to which the participants continued aspirin
use after completing scheduled treatment is not clear.
Table 5. Benefits and harms of 10 years of aspirin on mortality by age and sex
Age at starting 50 years 55 years 60 years 65 years
Mortality Baseline Reduction Baseline Reduction Baseline Reduction Baseline Reduction
Cancer
Men 7.45 0.99 (0.80) 11.59 1.48 (1.19) 16.40 2.04 (1.62) 20.53 2.41 (1.91)
Women 6.12 0.53 (0.39) 8.80 0.78 (0.58) 12.04 1.09 (0.82) 15.26 1.39 (1.06)
MI
Men 5.08 0.07 8.05 0.12 11.80 0.20 15.13 0.31
Women 1.80 0.02 3.44 0.04 6.02 0.08 9.33 0.14
Total
Men 12.53 1.05 (0.86) 19.64 1.60 (1.30) 28.19 2.24 (1.82) 35.66 2.72 (2.22)
Women 7.92 0.55 (0.40) 12.24 0.82 (0.61) 18.06 1.16 (0.89) 24.60 1.53 (1.20)
Adverse events Baseline Excess Baseline Excess Baseline Excess Baseline Excess
Stroke
Men 1.03 0.06 1.85 0.09 3.21 0.17 4.83 0.32
Women 0.74 0.04 1.47 0.06 2.90 0.11 5.12 0.26
GI bleeding
Men 0.19 0.04 (0.04) 0.34 0.05 (0.06) 0.57 0.08 (0.09) 0.74 0.17 (0.19)
Women 0.12 0.02 (0.03) 0.22 0.03 (0.04) 0.39 0.05 (0.06) 0.59 0.11 (0.13)
Peptic ulcer
Men 0.08 0.02 (0.02) 0.12 0.03 (0.03) 0.15 0.03 (0.04) 0.17 0.05 (0.06)
Women 0.07 0.02 (0.02) 0.10 0.02 (0.02) 0.13 0.03 (0.03) 0.16 0.04 (0.05)
Total
Men 1.29 0.11 (0.12) 2.31 0.17 (0.18) 3.93 0.28 (0.30) 5.73 0.54 (0.58)
Women 0.93 0.09 (0.09) 1.79 0.11 (0.12) 3.42 0.19 (0.21) 5.86 0.41 (0.44)
All-cause deaths Baseline Reduction Baseline Reduction Baseline Reduction Baseline Reduction
Men 18.02 0.94 (0.74) 27.67 1.43 (1.12) 41.99 1.96 (1.52) 58.74 2.18 (1.64)
Women 11.82 0.47 (0.31) 18.55 0.70 (0.49) 29.86 0.97 (0.69) 47.45 1.12 (0.76)
Baseline ‘20-year’ event-specific mortality probabilities and aspirin-related reductions (per 100 individuals) using best (and conservative) estimates for
prophylactic use of aspirin for 10 years on mortality due to cancer, myocardial infarction, stroke and aspirin-related adverse events (peptic ulcer and
gastrointestinal bleeding) according to sex and age at starting use.
Effects on cardiovascular and bleeding events are assumed to occur only during active treatment (10 years) and those for cancer do not start until after
5 years of use but persist for an additional 10 years after treatment completion. Baseline rates are for the entire 20-year period. Figures in parentheses
are conservative estimates.
The figures in bold represent overall benefits, overall harms and net balance of benefit and harm.
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Observational studies suggest greater effect sizes with longer dur-
ation of use [6, 7, 24] especially for more than 10 years of aspirin
use [26], but in the absence of long-term follow-up, these studies
are unable to determine the duration of beneﬁt after treatment ces-
sation. Further research is needed to investigate the duration of
cancer prevention effect after stopping the drug.
There is also uncertainty about whether there is an upper age
at which the harms outweigh the beneﬁts. For example the
balance of beneﬁt–harm in usage above the age of 70 may be dif-
ferent since bleeding events become more common and serious
after this age, but the cancer rates also become higher. Ongoing
ASPREE trial (ClinicalTrials.gov Identiﬁer: NCT01038583) may
help address the question of low-dose aspirin use in elderly.
There is also more heterogeneity and consequent uncertainty in
the results for women, with smaller effects seen in the WHS
trial, than in other studies.
The optimum dose for cancer prevention is also uncertain.
Indirect comparisons show little difference between low-dose
(75–100 mg/day) and standard-dose (300–325 mg/day) aspirin,
although there are no direct randomised comparisons. There is
no clear indication that doses higher than 300–325 mg are more
effective in general population, although they may be needed in
the adjuvant setting or for high-risk populations.
Although at current H. pylori prevalence, screen and treat
before starting prophylactic aspirin appears a reasonable strat-
egy, it may not remain cost-effective with declining prevalence.
A 2 × 2 × 2 factorial trial could address all three of these
questions—low versus standard dose, 5 versus 10 years duration
of use and H. pylori screen-and-treat versus symptom-directed
management. However, separate trials could be done if deemed
logistically more attractive.
Further research is also needed to identify additional (e.g.
genetic) factors associated with the risk of bleeding. Reliable data
on minor bleeding episodes in general population are sparse. These
events have an important inﬂuence on acceptability and adherence,
and research to gather such data are needed. Much still remains to
be learned in special populations at high risk, such as those with
Barrett’s oesophagus, where placebo-controlled trials are ongoing.
It is important that these are continued and completed.
In summary, analysis of beneﬁts and harms in the general
population in the developed world suggests a net beneﬁt for a
minimum 5 years of aspirin prophylaxis starting between ages
50 and 65, for both men and women, with larger beneﬁts for
10 years of use. Continuing aspirin use for a longer duration
also appears to be beneﬁcial; however, there is uncertainty about
the age at which it should be stopped.
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Figure 1. Cumulative effects of aspirin taken for 10 years starting at 55 years of age: on deaths over next 20 years in 100 average-risk men (A) and women (B).
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